Epitalon (Epithalon) vs PT-141 (Bremelanotide)

Side-by-side comparison of mechanisms, dosing, interactions, and stacking potential.

Epitalon (Epithalon)PT-141 (Bremelanotide)
CategoryPeptidesPeptides
Standard DoseResearch indicates 5-10 mg daily via subcutaneous injection for 10-20 day cycles.Research indicates 1.75 mg administered via subcutaneous injection approximately 45 minutes before anticipated sexual activity.
TimingEvening administration preferred (aligns with pineal/melatonin function). Some protocols split doses AM/PM.45-60 minutes before anticipated sexual activity. Effects last 6-72 hours depending on individual response.
Cycle Duration10-20 day intensive cycles repeated every 4-6 months. Not used continuously.As-needed basis. Not intended for daily use.
Evidence Levelanimal_plus_anecdotalstrong_human

Mechanism

Epitalon (Ala-Glu-Asp-Gly / AEDG) is a synthetic tetrapeptide based on the natural pineal gland peptide epithalamin. It activates telomerase by inducing expression of the catalytic subunit hTERT, resulting in telomere elongation averaging 33.3% in human somatic cells. Epitalon restores pineal melatonin synthesis and circadian gene expression in aged organisms, increases BDNF, and upregulates CREB1. It also modulates the neuroendocrine system through its effects on the hypothalamic-pituitary axis and antioxidant enzyme regulation.

Standard Dosing

Research indicates 5-10 mg daily via subcutaneous injection for 10-20 day cycles.

Timing

Evening administration preferred (aligns with pineal/melatonin function). Some protocols split doses AM/PM.

Cycle Duration

10-20 day intensive cycles repeated every 4-6 months. Not used continuously.

Side Effects

  • Injection site irritation
  • Mild drowsiness (evening dosing)
  • Vivid dreams

Contraindications

  • Active cancer (telomerase activation concern)
  • History of cancer within 5 years
  • Pregnancy and breastfeeding

Best Stacking Partners

GHK-CuMOTS-cHumanin

Mechanism

PT-141 (Bremelanotide) is a synthetic cyclic heptapeptide melanocortin analog that acts as an agonist at MC3R and MC4R melanocortin receptors, with higher affinity for MC4R. It enhances sexual desire by activating presynaptic MC4Rs on neurons in the medial preoptic area (mPOA) of the hypothalamus, increasing dopamine release — an excitatory neurotransmitter for sexual desire. Unlike PDE5 inhibitors, PT-141 works centrally through the CNS rather than peripherally on blood flow, addressing desire rather than just erectile mechanics.

Standard Dosing

Research indicates 1.75 mg administered via subcutaneous injection approximately 45 minutes before anticipated sexual activity.

Timing

45-60 minutes before anticipated sexual activity. Effects last 6-72 hours depending on individual response.

Cycle Duration

As-needed basis. Not intended for daily use.

Side Effects

  • Nausea (most common, dose-dependent)
  • Flushing
  • Headache
  • Nasal congestion (intranasal route)
  • Transient blood pressure increase
  • Skin darkening with repeated use

Contraindications

  • Uncontrolled hypertension
  • Cardiovascular disease
  • Pregnancy and breastfeeding
  • Use of other melanocortin agonists concurrently

Best Stacking Partners

Kisspeptin-10Melanotan II

Not sure which is right for you?

Take our free assessment to get personalized recommendations based on your health goals, current stack, and biomarkers.

Get Your Free Protocol →or take the assessment →